What the trial was testing
The BOREAS enrolled 939 patients with copd. The study was sponsored by Sanofi and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
People taking dupilumab had 30% fewer COPD flare-ups compared to those on standard treatment.
The New England journal of medicine · 2023 · NCT03930732
These findings — that people on dupilumab had fewer COPD flare-ups than those on standard treatment — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 939 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with copd, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Dupilumab is FDA-approved for this use as of 2024. If you have COPD with frequent flare-ups and high eosinophil counts despite using standard inhalers, talk to your doctor about whether dupilumab could help reduce your flare-ups and improve your breathing.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open copd trials
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.
Pulmonary Overdistension Assessment With Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrom in Prone Position.
Mechanical ventilation in COPD requires a good interaction Patient-Ventilator without asynchronies in order to reduce mortality. Dynamic hyperinflation with PEEPi is responsible for major asynchronies in COPD. It is supposed to be symmetrical between the 2 lungs with the same PEEPi. EIT can measure the distribution of tidal ventilation and interlung lung insufflation delay on the impedance time curve of each lung. Moreover, it is possible in intubated COPD patients to assess one lung PEEPi during low flow insufflation with pressure-EIT monitoring. This study aims to measure interlungs insufflation delay under mechanical ventilation in COPD patients